AMRX vs. AMPH, COLL, SVA, STML, PRGO, ASND, LEGN, CERE, VKTX, and ITCI
Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Collegium Pharmaceutical (COLL), Sinovac Biotech (SVA), Stemline Therapeutics (STML), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.
Amneal Pharmaceuticals (NASDAQ:AMRX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Amneal Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Amneal Pharmaceuticals currently has a consensus price target of $8.25, indicating a potential upside of 19.74%. Amphastar Pharmaceuticals has a consensus price target of $66.00, indicating a potential upside of 57.44%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Amphastar Pharmaceuticals and 8 mentions for Amneal Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.13 beat Amneal Pharmaceuticals' score of 0.92 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Amphastar Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amneal Pharmaceuticals' net margin of -6.76%. Amneal Pharmaceuticals' return on equity of 234.06% beat Amphastar Pharmaceuticals' return on equity.
Amphastar Pharmaceuticals received 377 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 66.67% of users gave Amphastar Pharmaceuticals an outperform vote.
Summary
Amphastar Pharmaceuticals beats Amneal Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Amneal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amneal Pharmaceuticals Competitors List
Related Companies and Tools
